Royal Bank of Canada (RBC) significantly increased its holdings in Tempus AI, Inc. (TEM) by 201.17% as reported in its 13F filing on May 15, 2025. This substantial increase in shares, which brought RBC's total reported value in TEM to $1.253 million, appears to be primarily driven by strong financial performance reported by Tempus AI and positive analyst sentiment leading up to the filing deadline.1
Key factors contributing to this increase likely include:
- Robust Q1 2025 Earnings: Tempus AI, Inc. released its first-quarter 2025 results on May 6, 2025, just nine days before RBC's 13F filing. The report highlighted a 75.4% year-over-year revenue increase to $255.7 million and a 99.8% year-over-year rise in gross profit. The company also announced strategic collaborations with AstraZeneca and Pathos, projecting an additional $200 million in data licensing and model development fees. Furthermore, Tempus AI raised its full-year 2025 revenue guidance to $1.25 billion, representing approximately 80% growth, and forecast positive Adjusted EBITDA of $5 million for the year.2
- Positive Analyst Coverage: Prior to the 13F filing, BTIG initiated coverage of Tempus AI with a "Buy" recommendation on April 21, 2025. Such positive analyst initiations can often influence institutional investment decisions.3
- Post-IPO Accumulation: Tempus AI conducted its Initial Public Offering (IPO) in 2024.4 Institutions often begin or increase their positions in newly public companies as more data becomes available and the company demonstrates its financial viability and growth trajectory.
The timing of RBC's reported increase aligns closely with these positive developments, suggesting that the strong financial outlook and strategic advancements of Tempus AI were compelling factors for the investment.
